Vincent N. Jarvis

Vincent Jarvis practices at Ocean Health Care Group in Fort Lauderdale, Florida.

Vincent Jarvis' NPI, 1548276538, was assigned on July 31, 2006. Vincent Jarvis holds New York license 165969.

Vincent Jarvis' primary practice is Ocean Health Care Group, at 2715 E Oakland Park Blvd Ste 101 Suite 101, Fort Lauderdale, FL 33306. The practice phone is (954) 996-2326. The NPI Registry lists Vincent Jarvis' practice address as 900 Business Center Dr, Horsham, PA 19044.

Vincent Jarvis' primary practice is Ocean Health Care Group in Fort Lauderdale, Florida. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Vincent Jarvis to 1 more physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Vincent Jarvis practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Vincent Jarvis' primary specialty in the NPI Registry, under taxonomy code 207R00000X. Vincent Jarvis is licensed in New York.

CMS data shows 1,481 Medicare services from Vincent Jarvis across 9 procedure codes in 2024, for 35 Medicare patients. Medicare paid $70,097 for them. Every service was in an office.

CMS counts 35 Medicare patients who saw Vincent Jarvis in 2024. The largest group is 65 to 74, with 22 patients. 75% of them have high cholesterol, and 74% have arthritis. Their average risk score is 0.94, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Vincent Jarvis' median patient age at 46, with 39% women.

In 2024, Vincent Jarvis wrote 59 Medicare Part D claims for 11 patients. 83% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $656 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

Vincent Jarvis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 94 general payments to Vincent Jarvis from 6 drug and device companies from 2016 to 2019. Speaker and faculty fees make up the largest share, 74% of the total. Gilead Sciences, Inc. paid the most, $32,797.